Cambrex Corporation was founded in 1981 and is based in East Rutherford, New Jersey. Cambrex Corporation, a life sciences company, provides products and services to develop and commercialize active pharmaceutical ingredients and advanced intermediates. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, and other custom chemicals derived from organic chemistry. The company sells its products through direct sales and independent agents to pharmaceutical and generic drug companies worldwide.

Santhera Pharmaceuticals Holding AG (Santhera) is a Swiss company focused on discovery, development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases. CATENA is Santhera’s first product approved in Canada for symptomatic treatment of Friedreich's ataxia. Santhera has five clinical-stage development programs, three of which investigate its core compound, SNT-MC17/idebenon, in the treatment of Friedreich’s ataxia, Duchenne muscular dystrophy and Leber’s hereditary optic neuropathy. Another clinical program investigates JP-1730/fipamezole in the treatment of dyskinesia in Parkinson’s disease. The fifth program concerns congenital muscular dystrophies. It operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, engaged in research and development of pharmaceuticals, Santhera Pharmaceuticals (Canada), Inc., active in marketing and sales of pharmaceuticals, and Santhera Pharmaceuticals (USA), Inc.

Obagi Medical Products, Inc. company was founded in 1988 and is headquartered in Long Beach, California. Obagi Medical Products, Inc. is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The Company develops and commercializes prescription-based products, topical skin health systems that enable physicians to treat a range of skin conditions, including pre-mature aging, photo-damage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, rosacea and soft tissue deficits, such as fine lines and wrinkles. The Company markets and sells a range of systems and related products for the enhancement of skin health. Its principal product line is its Obagi Nu-Derm System. Its Obagi Nu-Derm System is a prescription-based topical skin health system that enhances the skin's overall health by correcting photo damage using drugs that, by definition, work at the cellular level, resulting in a reduction of the visible signs of aging. In January 2009, the Company launched the Obagi Rosaclear System.

Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina. Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptors (NNR) Therapeutics for the treatment of multiple diseases and disorders of the central nervous system. The Company has clinical-stage product candidates for target indications in three therapeutic areas, which includes cognitive impairment, depression and anxiety, and pain. It also has preclinical programs focused in smoking cessation, addiction, obesity, pain, Parkinson’s disease and inflammation. The Company has collaboration with AstraZeneca and an alliance with GlaxoSmithKline. The drug discovery activities utilize computer-based molecular design methodologies and biological data for a library of compounds developed and collected over more than 20 years. The technologies are referred to as Pentad. The Company use Pentad to design or optimize AZD3480 (TC-1734), TC-5619, TC-2216 and TC-6499.

Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California. Aeolus Pharmaceuticals, Inc. (Aeolus) is a pharmaceutical company engaged in development of medical countermeasures against biological, chemical and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. The Company is testing its lead compound, AEOL 10150, in a range of indications each in various stages of development. The Company’s lead indications are a medical countermeasure against the effects of acute radiation syndrome (ARS) in the lungs and in the gastro-intestinal tract, and a medical countermeasure against the effects of sulfur mustard gas and chlorine gas. The Company is also developing its second drug candidate AEOL 11207 for the treatment of epilepsy and Parkinson’s disease.

Oragenics, Inc. company was founded in 1996 and is based in Alachua, Florida. Oragenics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of products and technologies associated with oral health, antibiotics, and other general health benefits. The company develops Probiora3, an oral probiotics technology that employs three natural strains of beneficial bacteria, which promote oral health; LPT3-04 for weight loss; and DPOLT or differentially protected orthogonal lantionine technology, which is a solid or liquid phase peptide synthesis platform technology that has various applications for the manufacture of commercially important bioactive peptides. It is also developing Mutacin 1140, an antibiotic with antimicrobial activity against gram-positive bacteria, including methicillin-resistant and vancomycin-resistant Staphylococcus aureus; Proteomic-based In-Vivo Induced Antigen Technology (PIVIAT) and Proteomic-based Change Mediated Antigen Technology (PCMAT) diagnostic platforms that enable the identification of novel and potentially important gene targets associated with the natural onset and progression of infections, cancers, and other diseases in humans and other living organisms, including plants; and SMaRT Replacement Therapy, which is a painless topical treatment for protection against tooth decay. The company primarily operates in the United States and Mexico. It was formerly known as Oragen, Inc.

Hi-Tech Pharmacal Co., Inc. was founded in 1982 and is based in Amityville, New York. Hi-Tech Pharmacal Co., Inc. (Hi-Tech) is a specialty manufacturer and marketer of prescription, over-the-counter (OTC) and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and OTC brands. It produce a range of products for various disease states, including asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care, neurological disorders, glaucoma and other conditions. The Company’s generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments, as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. On February 27, 2009, the Company purchased substantially all of the assets of E. Claiborne Robins Company, Inc. doing business as, ECR Pharmaceuticals (ECR Pharmaceuticals or ECR).

ProStrakan Group plc company specializes in those areas, but also focuses on therapies for women's health and issues relating to the ageing male. ProStrakan's marketed products include brain tumor treatment Bélustine and bone therapy Adcal. Products in development include therapies to treat alopecia and hypogonadism. ProStrakan markets its products to more than 10 countries in the EU, and has applied for FDA approval of pain medication Abstral in the US. ProStrakan company was founded as Strakan in 1995 by Chairman Harry Stratford and changed its name to ProStrakan when it merged with ProSkelia. Warbug Pincus and Aventis Pharma each hold majority shares in the company.

Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.

Nutra Pharma Corporation was founded in 2000 and is based in Boca Raton, Florida. Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.